VTechWorks staff will be away for the Thanksgiving holiday beginning at noon on Wednesday, November 22, through Friday, November 24, and will not be replying to requests during this time. Thank you for your patience, and happy holidays!
Development of a live, attenuated, recombinant vaccine for Brucellosis
A recombinant, attenuated strain of Brucella suis or Brucella melitensis with a deficiency in carboxyl-terminal protease activity or tail-specific protease activity can be used as a vaccine for the prevention or treatment of Brucellosis. Prior exposure to the Brucella species is identified by detecting a genetic sequence for carboxyl-terminal (i.e. tail-specific) protease activity in a biological sample.